Auna (AUNA) Q3 2026 earnings review

Auna cuts its profit outlook as Colombian medical costs rise

Auna, the operator of hospitals and cancer plans in Mexico, Peru and Colombia, grew sales while medical costs squeezed its profit margins. Third-quarter revenue rose 10% in constant currency to S/1,325 million as surgery counts climbed across all three countries. Operating profit before depreciation and one-offs fell 5% in constant currency because a loss-making cancer contract and government drug price caps hit Colombia, while prior-year billing penalties dragged on Peru. Executive chairman Suso Zamora cut the full-year profit forecast to flat or slightly down.

At a glance
Constant-currency revenue growth+10% +19% as reported (S/1,325M)
Operating profit (Adjusted EBITDA)S/231M -4.6% in constant currency; 17.5% margin
Nine-month free cash flowS/626M +95% from a year ago; net debt at 3.5x
Full-year profit outlookCut stable or slightly down vs 10%–14% growth prior

⚖️ Verdict: 🔴 Bearish

The story got worse because the steep second-half profit rebound the company's earlier plan relied on failed to arrive. Colombia's shift toward fixed-fee insurer contracts backfired when advanced cancer cases exceeded assumptions on a 500,000-person deal, forcing Auna to cancel the contract and abandon its target of at least 10% profit growth. On the positive side, Monterrey hospital profit grew from a year ago for the first time in 2026, and tax refunds plus faster collections almost doubled nine-month free cash flow.

The question now is whether cancelling the Colombian contract stops the margin drop or if drug price caps and Peruvian billing penalties keep earnings down. If the bad contract caused most of the damage, margins recover as Mexico fills more beds; if government caps and insurer deductions are permanent, profit stays lower. Fourth-quarter margins in Colombia and Peru will show which side is right.

🐂 Bull Case

🟢🟢 strengthening GROWTH

Monterrey Hospital Recovery Returns Mexico to Profit Growth

Auna runs hospitals and insurance plans in Mexico, which bring in 24% of group sales and 36% of operating profit before depreciation and one-offs (Adjusted EBITDA). After falling in the first half of 2026, Mexican profit rose 5% in local currency this quarter. Executive chairman Suso Zamora credited commercial changes in the Monterrey hospital network, where revenue grew 18% and profit rose 10%.

  • Doctors Hospital key insurers: patient volumes up 25% and revenue up 63% from a year ago
  • Monterrey cancer care: chemotherapy and radiation revenue up 73%, reaching 10% of network sales
  • Total bed occupancy in Mexico: 41.1%, up 2.0 percentage points from last quarter and last year
  • Doctor recruitment: 28 new doctors met minimum billing targets for at least two months

Better agreements with insurers are filling beds because patients face lower barriers at Doctors Hospital, Auna's largest Mexican clinic. That hospital growth overcame flat sales and new value-added tax limits at Auna Seguros, its Mexican insurance arm. What to watch: Mexican bed occupancy and cancer treatment volumes in the fourth quarter. A second quarter of rising occupancy would show the new doctors are keeping surgical suites busy.

🟢 strengthening CASH

Tax Refunds and Collections Almost Double Free Cash Flow

Cash generation remains a bright spot while hospital margins shrink, though investors worry that stretched supplier payments carry reversal risk. Over the first nine months of 2026, free cash flow (operating cash flow minus investing cash outflows) rose 95% to S/626 million, or about S/226 million in the third quarter alone by our math. Net debt fell 8.6% from a year ago to S/3,133 million.

Faster customer collections in Peru and Mexico added S/172 million to nine-month operating cash, and tax recoveries in Colombia saved another S/101 million. That cash lifted Auna's bank balance to S/614 million and trimmed its net debt to 3.5 times annual Adjusted EBITDA, down from 3.6 times in June. However, the healthcare group still takes 142 days on average to pay suppliers, and tax refunds do not repeat every quarter.

What to watch: fourth-quarter operating cash flow and supplier payment days. If Auna generates cash without leaning further on suppliers, net debt can keep moving toward its target of below 3.0 times profit.

🐻 Bear Case

🔴🔴 new MACRO contradicts narrative

Colombia Cancer Contract and Price Caps Force Profit Cut

Auna has expanded its prospective global payment (PGP) contracts in Colombia, which pay a fixed fee per insured person and accounted for 23% of Colombian revenue this quarter, down from 24% last quarter. Management previously promoted these risk-sharing deals for predictable cash flow and clinical efficiency. Instead, one cancer contract started in 2025 covering 500,000 people suffered "extraordinary adverse medical-costs under a specific oncology risk-sharing contract" because advanced cancer cases far exceeded estimates.

Colombian regulators also imposed "regulatory price caps on certain high-cost oncology medications" in mid-August, and statutory workweek cuts raised overtime pay. As a result, Colombian segment Adjusted EBITDA fell 30% in local currency to S/43 million, and the segment margin dropped 5.1 percentage points to 8.8%. The healthcare operator cancelled the loss-making contract after quarter-end, shedding about 4% of Colombian sales, and cut its full-year group profit outlook.

What to watch: Colombia's fourth-quarter segment margin after the contract exit. Because the August drug price caps only hit half of the third quarter, the next results will show their full weight on pharmacy profits.

🔴🔴 persistent MARGIN

Cost of Services Pushes Margin Down for Sixth Quarter

Group revenue grew 19% as reported and 10% in constant currency to S/1,325 million, but higher patient volumes did not lift the bottom line. Consolidated Adjusted EBITDA was flat as reported at S/231 million and fell 4.6% in constant currency. That pushed the Adjusted EBITDA margin down 3.3 percentage points from a year ago to 17.5%, down from 18.4% in the second quarter.

The pressure sits in the direct cost of running hospitals and health plans. Cost of sales and services rose 26% to S/879 million, climbing 3.9 percentage points as a share of revenue to 66.3% and cutting gross margin to 33.7%. Drug expenses for new corporate members in Peru, higher nursing payrolls, and Colombian treatment costs all outpaced price increases, while administrative expenses stayed flat as a share of sales.

What to watch: consolidated gross margin and the medical loss ratio (the share of plan revenue spent on medical care) in the fourth quarter. Margin recovery requires pharmacy and clinical payroll costs to grow slower than hospital billings.

🔴 persistent GROWTH

Peru Billing Penalties Persist While Memberships Dip

Peru is Auna's largest profit center, combining its hospital network and Oncosalud, its prepaid cancer and general health plan business. Consolidated Peruvian revenue rose 6% from a year ago to S/516 million, but segment Adjusted EBITDA fell 6% to S/104 million. Within that total, hospital profit dropped 16% to S/37 million because of "penalties arising from the reconciliation of prior years’ receivables" with insurers, a drag that has now hit three quarters in a row.

At Oncosalud, total plan memberships fell 2% from the second quarter to 1,441,794, a drop of about 30,200 members by our math, while higher-margin cancer plan memberships slipped 3% to 973,000. Meanwhile, the number of patients treated jumped 34% from a year ago as newly signed corporate accounts used more care, lifting the nine-month medical loss ratio by 4.2 percentage points to 58.7%.

What to watch: whether Auna closes all prior-year Peruvian billing disputes by the fourth quarter as finance chief Gisele Remy previously planned, and whether two new corporate deals for 4,000 members reverse the membership dip.

👓 Other Themes

new PRODUCT

Trecca Outpatient Project Enters Construction in Lima

On November 3, 2026, Auna began building the Centro Ambulatorio Trecca in Lima under a 20-year public-private partnership with EsSalud, Peru's public social health insurer. Structured as a "capital-light concession ring-fenced at the project level", the 23-story clinic will be reimbursed for construction through progress certificates. When it opens in late 2028, Auna expects the center to handle over three million annual visits from six million insured Lima residents.

💲 Other KPIs

Net finance cost (26Q3) S/112 million
⇗ accelerating

Reported net finance costs rose 56% from S/72 million a year ago, which cut net income more than in half to S/24 million. The jump happened because a S/40 million non-cash currency gain in last year's third quarter did not repeat after Auna reset its currency hedges. Excluding non-cash items, cash interest and finance costs edged down 3% to S/107 million.

Total hospital capacity utilization (26Q3) 69.5%
⇗ accelerating

Bed occupancy across all 2,252 hospital beds rose 3.1 percentage points from a year ago and 2.9 points from the second quarter. Utilization reached 89.2% in Peru, 80.3% in Colombia after Montería added beds, and 41.1% in Mexico. Total surgeries across the group grew 12% from a year ago to 23,932.

🔮 Guidance

FY26 Revenue growth (constant currency) 10%–14%
🠆 unchanged from 10%–14% (~12% midpoint)
⇗ accelerating

Unchanged. Management kept its full-year target of 10% to 14% constant-currency sales growth. After growing 10% in the first quarter, 9% in the second, and 10% in the third, hitting the 12% middle of the range requires about 19% constant-currency growth in the fourth quarter by our math, or about 11% just to reach the 10% floor.

FY26 Adjusted EBITDA growth Broadly stable or slightly down YoY
🠇 cut from Low end of 10%–14% FX-neutral growth (excl. Peru penalties)
⇄ reversing

Cut. On October 22, the company lowered its full-year operating profit plan from at least 10% constant-currency growth to "broadly stable or slightly down year-over-year" because of Colombian cancer care losses and drug price caps. Through nine months, reported Adjusted EBITDA is down 3% at S/676 million. By our math, finishing the year flat against last year's S/917 million requires fourth-quarter profit to rise about 10% to S/241 million.

FY26 Capital expenditures ~4% of consolidated revenues
🠆 unchanged from ~4% of consolidated revenues
⇗ accelerating

Unchanged. The group still plans to spend about 4% of revenue on capital projects this year. Through the first nine months, maintenance capital spending was S/111 million, or 3.0% of revenue by our math, which leaves room for higher equipment spending in the fourth quarter.

❓ Key Questions

How much did Peruvian billing penalties cost in Q3?

Auna said Peruvian profit would have been flat without prior-year receivable penalties, which implies a drag of roughly S/7 million by our math. Management has not disclosed the exact penalty amount for two straight quarters or confirmed if all disputes will close by year-end.

What will Colombian drug price caps cost over a full quarter?

Government price caps on high-cost cancer drugs took effect in mid-August, hurting only half of the third quarter. Investors need to know how much of Colombia's S/8 million profit drop came from the cancelled contract versus the permanent drug caps.

Why did Oncosalud lose 30,000 plan members since June?

Total plan memberships in Peru fell 2% from the second quarter to 1.44 million, and cancer plan members fell 3% to 973,000. Management highlighted new corporate deals for 4,000 members but did not explain the larger drop in existing individual plans.

Did Monterrey open its new radiation machine in September?

Last quarter, executives said Auna would inaugurate an Elekta EVO linear accelerator in Monterrey in September 2026 after an earlier delay. The third-quarter release mentions higher radiation volumes in Mexico but gives no update on whether the machine is running.